Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 746-756

  Yulyana, Yulyana ^a   Ho, Ivy A W ^a   Sia, Kian Chuan ^a   Newman, Jennifer P ^a   Toh, Xin Yi ^a   Endaya, Berwini B ^b   Chan, Jerry K Y ^c,d,e   Gnecchi, Massimiliano ^f,g,h   Huynh, Hung ^a   Chung, Alexander Y F ⁱ   Lim, Kiat Hon ⁱ   Leong, Hui Sun ^a   Iyer, Narayanan Gopalakrishna ^a   Hui, Kam Man ^a,c,e,j   Lam, Paula Y P ^a,c,e  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b GRIFFITH UNIVERSITY   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; CARBANILAMIDE DERIVATIVE; CONDITIONED MEDIUM; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN TARGETING; THERAPY EFFECT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CONDITIONED MEDIUM; CYTOLOGY; FETUS; GENETICS; LIVER NEOPLASMS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FETUS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; LIVER NEOPLASMS; MESENCHYMAL STROMAL CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84927006767     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.13     Document Type: Article

References (50)

1. Cheng, AL, Kang, YK, Chen, Z, Tsao, CJ, Qin, S, Kim, JS et al. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
2. Cabibbo, G, Rolle, E, De Giorgio, M, Genco, C, Pressiani, T, Spada, F et al.; HCC Working Group. (2011). Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther 11: 1807-1816.
3. Keating, A (2012). Mesenchymal stromal cells: new directions. Cell Stem Cell 10: 709-716.
4. Lee, KD, Kuo, TK, Whang-Peng, J, Chung, YF, Lin, CT, Chou, SH et al. (2004). In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40: 1275-1284.
5. Sun, B, Roh, KH, Park, JR, Lee, SR, Park, SB, Jung, JW et al. (2009). Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 11: 289-98, 1 p following 298.
6. Gao, Y, Yao, A, Zhang, W, Lu, S, Yu, Y, Deng, L et al. (2010). Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 29: 2784-2794.
7. Yulyana, Y, Endaya, BB, Ng, WH, Guo, CM, Hui, KM, Lam, PY et al. (2013). Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Stem Cells Dev 22: 1870-1882.
8. Xie, C, Xie, DY, Lin, BL, Zhang, GL, Wang, PP, Peng, L et al. (2013). Interferon-â gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway. Br J Cancer 109: 1198-1205.
9. Ong, HT, Federspiel, MJ, Guo, CM, Ooi, LL, Russell, SJ, Peng, KW et al. (2013). Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol 59: 999-1006.
10. Klopp, AH, Gupta, A, Spaeth, E, Andreeff, M and Marini, F 3rd (2011). Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19.
11. Gnecchi, M, Zhang, Z, Ni, A and Dzau, VJ (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103: 1204-1219.
12. Potapova, IA, Gaudette, GR, Brink, PR, Robinson, RB, Rosen, MR, Cohen, IS et al. (2007). Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 25: 1761-1768.
13. Watson, SL, Marcal, H, Sarris, M, Di Girolamo, N, Coroneo, MT and Wakefield, D (2010). The effect of mesenchymal stem cell conditioned media on corneal stromal fibroblast wound healing activities. Br J Ophthalmol 94: 1067-1073.
14. Li, T, Yan, Y, Wang, B, Qian, H, Zhang, X, Shen, L et al. (2013). Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 22: 845-854.
15. Jitraruch, S, Mitry, RR and Dhawan, A (2013). Intraportal transplantation of human bone marrow mesenchymal stem cells in pigs with fulminant hepatic failure. Hepatology 57: 2088.
16. Gauthaman, K, Yee, FC, Cheyyatraivendran, S, Biswas, A, Choolani, M and Bongso, A (2012). Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem 113: 2027-2039.
17. Ho, IA, Toh, HC, Ng, WH, Teo, YL, Guo, CM, Hui, KM et al. (2013). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31: 146-155.
18. Karp, JM and Leng Teo, GS (2009). Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4: 206-216.
19. Colombino, M, Sperlongano, P, Izzo, F, Tatangelo, F, Botti, G, Lombardi, A et al. (2012). BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 3: e259.
20. Breuhahn, K and Schirmacher, P (2008). Reactivation of the insulin-like growth factor- II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 14: 1690-1698.
21. Whittaker, S, Marais, R and Zhu, AX (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
22. Tovar, V, Alsinet, C, Villanueva, A, Hoshida, Y, Chiang, DY, Sole, M et al. (2010). IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52: 550-559.
23. Sun, B and Karin, M (2008). NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27: 6228-6244.
24. Malaguarnera, R and Belfiore, A (2014). The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) 5: 10.
25. Leong, HS, Chong, FT, Sew, PH, Lau, DP, Wong, BH, Teh, BT et al. (2014). Targeting cancer stem cell plasticity through modulation of epidermal growth factor and insulinlike growth factor receptor signaling in head and neck squamous cell cancer. Stem Cells Transl Med 3: 1055-1065.
26. Clay, MR, Tabor, M, Owen, JH, Carey, TE, Bradford, CR, Wolf, GT et al. (2010). Singlemarker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32: 1195-1201.
27. Foulstone, E, Prince, S, Zaccheo, O, Burns, JL, Harper, J, Jacobs, C et al. (2005). Insulinlike growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205: 145-153.
28. Oka, Y, Waterland, RA, Killian, JK, Nolan, CM, Jang, HS, Tohara, K et al. (2002). M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 35: 1153-1163.
29. Breuhahn, K, Vreden, S, Haddad, R, Beckebaum, S, Stippel, D, Flemming, P et al. (2004). Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64: 6058-6064.
30. Desbois-Mouthon, C, Baron, A, Blivet-Van Eggelpoel, MJ, Fartoux, L, Venot, C, Bladt, F et al. (2009). Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15: 5445-5456.
31. Huynh, H, Chow, PK, Ooi, LL and Soo, KC (2002). A possible role for insulinlike growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13: 115-122.
32. Gong, Y, Cui, L and Minuk, GY (2000). The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 207: 101-104.
33. Zhang, ZY, Teoh, SH, Chong, MS, Lee, ES, Tan, LG, Mattar, CN et al. (2010). Neovascularization and bone formation mediated by fetal mesenchymal stem cell tissueengineered bone grafts in critical-size femoral defects. Biomaterials 31: 608-620.
34. Zhao, W, Ren, G, Zhang, L, Zhang, Z, Liu, J, Kuang, P et al. (2012). Efficacy of mesenchymal stem cells derived from human adipose tissue in inhibition of hepatocellular carcinoma cells in vitro. Cancer Biother Radiopharm 27: 606-613.
35. Giuffrida, D, Rogers, IM, Nagy, A, Calogero, AE, Brown, TJ and Casper, RF (2009). Human embryonic stem cells secrete soluble factors that inhibit cancer cell growth. Cell Prolif 42: 788-798.
36. Han, I, Yun, M, Kim, EO, Kim, B, Jung, MH and Kim, SH (2014). Umbilical cord tissuederived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling. Stem Cell Res Ther 5: 54.
37. Gong, P, Wang, Y, Wang, Y, Jin, S, Luo, H, Zhang, J et al. (2013). Effect of bone marrow mesenchymal stem cells on hepatocellular carcinoma in microcirculation. Tumour Biol 34: 2161-2168.
38. Hernanda, PY, Pedroza-Gonzalez, A, van der Laan, LJ, Broker, ME, Hoogduijn, MJ, Ijzermans, JN et al. (2013). Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis 34: 2330-2340.
39. Shen, H (2013). Stricter standards sought to curb stem-cell confusion. Nature 499: 389.
40. Mamede, AC, Laranjo, M, Carvalho, MJ, Abrantes, AM, Pires, AS, Brito, AF et al. (2014). Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study. J Membr Biol 247: 357-360.
41. Scagliotti, GV and Novello, S (2012). The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38: 292-302.
42. Toyoshima, H and Hunter, T (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74.
43. Nishida, N, Fukuda, Y, Komeda, T, Kita, R, Sando, T, Furukawa, M et al. (1994). Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54: 3107-3110.
44. Ranke, MB, Maier, KP, Schweizer, R, Stadler, B, Schleicher, S, Elmlinger, MW et al. (2003). Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 60: 174-180.
45. Chen, D, Yoo, BK, Santhekadur, PK, Gredler, R, Bhutia, SK, Das, SK et al. (2011). Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin Cancer Res 17: 6693-6701.
46. Hanafusa, T, Yumoto, Y, Nouso, K, Nakatsukasa, H, Onishi, T, Fujikawa, T et al. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176: 149-158.
47. Monticone, M, Liu, Y, Tonachini, L, Mastrogiacomo, M, Parodi, S, Quarto, R et al. (2004). Gene expression profile of human bone marrow stromal cells determined by restriction fragment differential display analysis. J Cell Biochem 92: 733-744.
48. Lalou, C, Lassarre, C and Binoux, M (1996). A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137: 3206-3212.
49. Moreno, MJ, Ball, M, Rukhlova, M, Slinn, J, L'abbe, D, Iqbal, U et al. (2013). IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity. Neoplasia 15: 554-567.
50. Shen, H, Fang, Y, Dong, W, Mu, X, Liu, Q and Du, J (2012). IGF-1 receptor is downregulated by sunitinib induces MDM2-dependent ubiquitination. FEBS Open Bio 2: 1-5.